Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus

被引：25

作者：

Thuret, Isabelle ^{[1
]}

Chaix, Marie-Laure ^{[2
,3
]}

Tamalet, Catherine ^{[4
]}

Reliquet, Veronique ^{[5
]}

Firtion, Ghislaine ^{[6
]}

Tricoire, Joelle ^{[7
]}

Rabaud, Christian ^{[8
]}

Frange, Pierre ^{[3
,9
]}

Aumaitre, Hugues ^{[10
]}

Blanche, Stephane ^{[3
,9
]}

机构：

[1] CHU Timone, Serv Hematol Pediat, Marseille, France

[2] Hop Necker Enfants Malad, AP HP, Virol Lab, Paris, France

[3] Univ Paris 05, EA 3620, Paris, France

[4] CHU Timone, Virol Lab, Marseille, France

[5] CHU Hotel Dieu, Serv Malad Infect, Nantes, France

[6] CHU Cochin, Grp Hosp, Paris, France

[7] CHU Purpan, Serv Pediat, Toulouse, France

[8] CHU Vandoeuvre Nancy, Serv Infectiol, Nancy, France

[9] Hop Necker Enfants Malad, AP HP, Serv Immunol Hematol Pediat, Paris, France

[10] Hop Perpignan, Serv Med Infect & Malad Trop, Perpignan, France

来源：

AIDS | 2009年 / 23卷 / 17期

关键词：

EXPERIENCED HIV-1-INFECTED PATIENTS; PLACEBO-CONTROLLED TRIAL; TMC125; ETRAVIRINE; HIV-1; INFECTION; DOUBLE-BLIND; EFFICACY; SAFETY; TMC114/RITONAVIR;

D O I：

10.1097/QAD.0b013e328331a456

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Twelve heavily pretreated, perinatally infected adolescents in virological failure were treated with a combination of raltegravir, r-darunavir and etravirine, as part of an expanded access program in France. After a 12-month median follow-up, viral load was <400 copies/ml in 11 (<50 in six). No grade > 2 side effects were recorded. Additional data and marketing authorizations are awaited, but preliminary results in adolescents with extensive multidrug resistant virus are encouraging.

引用

页码：2364 / 2366

页数：3

共 12 条

[1]

*ATU, NOT APPL TEMP AUTH U

[2] Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection [J].

Cooper, David A. ;

Steigbigel, Roy T. ;

Gatell, Jose M. ;

Rockstroh, Jurgen K. ;

Katlama, Christine ;

Yeni, Patrick ;

Lazzarin, Adriano ;

Clotet, Bonaventura ;

Kumar, Princy N. ;

Eron, Joseph E. ;

Schechter, Mauro ;

Markowitz, Martin ;

Loutfy, Mona R. ;

Lennox, Jeffrey L. ;

Zhao, Jing ;

Chen, Joshua ;

Ryan, Desmond M. ;

Rhodes, Rand R. ;

Killar, John A. ;

Gilde, Lucinda R. ;

Strohmaier, Kim M. ;

Meibohm, Anne R. ;

Miller, Michael D. ;

Hazuda, Daria J. ;

Nessly, Michael L. ;

DiNubile, Mark J. ;

Isaacs, Robin D. ;

Teppler, Hedy ;

Nguyen, Bach-Yen .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :355-365

[3]

*DIR PR P YEN, 2008, PRIS CHARG MED PERS

[4] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[5] Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients [J].

Haubrich, Richard ;

Berger, Dan ;

Chiliade, Philippe ;

Colson, Amy ;

Conant, Marcus ;

Gallant, Joel ;

Wilkin, Timothy ;

Nadler, Jeffrey ;

Pierone, Gerald ;

Saag, Michael ;

van Baelen, Ben ;

Lefebvre, Eric .

AIDS, 2007, 21 (06) :F11-F18

[6] Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 [J].

Katlama, Christine ;

Esposito, Roberto ;

Gatell, Jose M. ;

Goffard, Jean-Christophe ;

Grinsztejn, Beatriz ;

Pozniak, Anton ;

Rockstroh, Jurgen ;

Stoehr, Albrecht ;

Vetter, Norbert ;

Yeni, Patrick ;

Parys, Wim ;

Vangeneugdenk, Tony .

AIDS, 2007, 21 (04) :395-402

[7] Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial [J].

Lazzarin, Adriano ;

Campbell, Thomas ;

Clotet, Bonaventura ;

Johnson, Margaret ;

Katlama, Christine ;

Moll, Arend ;

Towner, William ;

Trortier, Benoit ;

Peeters, Monika ;

Vingerhoets, Johan ;

de Smedt, Goedele ;

Baeten, Benny ;

Beets, Greet ;

Sinha, Rekha ;

Woodfall, Brian .

LANCET, 2007, 370 (9581) :39-48

[8] Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial [J].

Madruga, Jose Valdez ;

Cahn, Pedro ;

Grinsztejn, Beatriz ;

Haubrich, Richard ;

Lalezari, Jacob ;

Mills, Anthony ;

Pialoux, Gilles ;

Wilkin, Timothy ;

Peeters, Monika ;

Vingerhoets, Johan ;

de Smedt, Goedele ;

Leopold, Lorant ;

Trefiglio, Roberto ;

Woodfall, Brion .

LANCET, 2007, 370 (9581) :29-38

[9] Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN:: a randomised controlled phase III trial [J].

Madruga, Jose Valdez ;

Berger, Daniel ;

McMurchie, Marilyn ;

Suter, Fredy ;

Banhegyi, Denes ;

Ruxrungtham, Kiat ;

Norris, Dorece ;

Lefebvre, Eric ;

de Bethune, Marie-Pierre ;

Tomaka, Frank ;

De Pauw, Martine ;

Vangeneugden, Tony ;

Spinoso-Guzman, Sabrina .

LANCET, 2007, 370 (9581) :49-58

[10] Raltegravir with optimized background therapy for resistant HIV-1 infection [J].

Steigbigel, Roy T. ;

Cooper, David A. ;

Kumar, Princy N. ;

Eron, Joseph E. ;

Schechter, Mauro ;

Markowitz, Martin ;

Loutfy, Mona R. ;

Lennox, Jeffrey L. ;

Gatell, Jose M. ;

Rockstroh, Jurgen K. ;

Katlama, Christine ;

Yeni, Patrick ;

Lazzarin, Adriano ;

Clotet, Bonaventura ;

Zhao, Jing ;

Chen, Joshua ;

Ryan, Desmond M. ;

Rhodes, Rand R. ;

Killar, John A. ;

Gilde, Lucinda R. ;

Strohmaier, Kim M. ;

Meibohm, Anne R. ;

Miller, Michael D. ;

Hazuda, Daria J. ;

Nessly, Michael L. ;

DiNubile, Mark J. ;

Isaacs, Robin D. ;

Nguyen, Bach-Yen ;

Teppler, Hedy .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :339-354

← 1 2 →